Literature DB >> 24996933

Neuroimmunomodulation in depression: a review of inflammatory cytokines involved in this process.

Helena M Abelaira1, Gislaine Z Réus, Fabricia Petronilho, Tatiana Barichello, João Quevedo.   

Abstract

Depression is a debilitating mental disease that affects a large number of people globally; however the pathophysiological mechanisms of this disease remain incompletely understood. Some studies have shown that depression is associated with inflammatory activity, and the mode of action of several antidepressants appears to involve immunomodulation. In this case, the induction of a pro-inflammatory state in healthy or depressive subjects induces a 'sickness behaviour' resembling depressive symptomatology. Potential mechanisms of pro-inflammatory cytokines are effects on monoamine levels, disruption of the hypothalamic-pituitary-adrenal axis, activation of the pathological microglial cells, such as the macrophages and alterations in neuroplasticity and brain functions. Thus, this review will highlight the role of inflammation in depression, the possible mechanisms involved, and also explore effective treatments that act on the immune system.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24996933     DOI: 10.1007/s11064-014-1372-5

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  88 in total

1.  Cytokine production and treatment response in major depressive disorder.

Authors:  S Lanquillon; J C Krieg; U Bening-Abu-Shach; H Vedder
Journal:  Neuropsychopharmacology       Date:  2000-04       Impact factor: 7.853

2.  Possible antidepressant effect of minocycline.

Authors:  J Levine; A Cholestoy; J Zimmerman
Journal:  Am J Psychiatry       Date:  1996-04       Impact factor: 18.112

3.  Changes in noradrenergic sensitivity to tumor necrosis factor-alpha in brains of rats administered clonidine.

Authors:  T A Ignatowski; R C Chou; R N Spengler
Journal:  J Neuroimmunol       Date:  1996-10       Impact factor: 3.478

4.  Cytokines and serotonin transporter in patients with major depression.

Authors:  Chiung-Wen Tsao; Yee-Shin Lin; Chwen-Cheng Chen; Chyi-Huey Bai; Shin-Rung Wu
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-03-06       Impact factor: 5.067

5.  Tumor necrosis factor-alpha-induced sickness behavior is impaired by central administration of an inhibitor of c-jun N-terminal kinase.

Authors:  K Palin; R H McCusker; K Strle; F Moos; R Dantzer; K W Kelley
Journal:  Psychopharmacology (Berl)       Date:  2008-02-12       Impact factor: 4.530

6.  Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression.

Authors:  M Maes; E Bosmans; R De Jongh; G Kenis; E Vandoolaeghe; H Neels
Journal:  Cytokine       Date:  1997-11       Impact factor: 3.861

7.  Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity.

Authors:  Daniel Lindqvist; Shorena Janelidze; Peter Hagell; Sophie Erhardt; Martin Samuelsson; Lennart Minthon; Oskar Hansson; Maria Björkqvist; Lil Träskman-Bendz; Lena Brundin
Journal:  Biol Psychiatry       Date:  2009-03-06       Impact factor: 13.382

8.  The macrophage theory of depression.

Authors:  R S Smith
Journal:  Med Hypotheses       Date:  1991-08       Impact factor: 1.538

9.  Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression.

Authors:  I Goshen; T Kreisel; O Ben-Menachem-Zidon; T Licht; J Weidenfeld; T Ben-Hur; R Yirmiya
Journal:  Mol Psychiatry       Date:  2007-08-14       Impact factor: 15.992

10.  Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression.

Authors:  Reiji Yoshimura; Hikaru Hori; Atsuko Ikenouchi-Sugita; Wakako Umene-Nakano; Nobuhisa Ueda; Jun Nakamura
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2009-03-28       Impact factor: 5.067

View more
  5 in total

Review 1.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 1. Disease Burden and Principles of Care.

Authors:  Raymond W Lam; Diane McIntosh; JianLi Wang; Murray W Enns; Theo Kolivakis; Erin E Michalak; Jitender Sareen; Wei-Yi Song; Sidney H Kennedy; Glenda M MacQueen; Roumen V Milev; Sagar V Parikh; Arun V Ravindran
Journal:  Can J Psychiatry       Date:  2016-08-02       Impact factor: 4.356

2.  Ketamine Exhibits Different Neuroanatomical Profile After Mammalian Target of Rapamycin Inhibition in the Prefrontal Cortex: the Role of Inflammation and Oxidative Stress.

Authors:  Helena M Abelaira; Gislaine Z Réus; Zuleide M Ignácio; Maria Augusta B Dos Santos; Airam B de Moura; Danyela Matos; Júlia P Demo; Júlia B I da Silva; Lucineia G Danielski; Fabricia Petronilho; André F Carvalho; João Quevedo
Journal:  Mol Neurobiol       Date:  2016-09-02       Impact factor: 5.590

3.  Inflammatory processes and schizophrenia: two independent lines of evidence from a study of twins discordant and concordant for schizophrenic disorders.

Authors:  Silke Braun; René Bridler; Norbert Müller; Markus J Schwarz; Erich Seifritz; Matthias Weisbrod; Alexandra Zgraggen; Hans H Stassen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-04-04       Impact factor: 5.270

Review 4.  Changes in Hippocampal Plasticity in Depression and Therapeutic Approaches Influencing These Changes.

Authors:  Wenbo Xu; Xiaoxiao Yao; Fangyi Zhao; Haisheng Zhao; Ziqian Cheng; Wei Yang; Ranji Cui; Songbai Xu; Bingjin Li
Journal:  Neural Plast       Date:  2020-11-26       Impact factor: 3.599

5.  Comorbidity Between Recent Diagnosis of Type 2 Diabetes and Non-Psychotic Psychiatric Disorders: Metabolic Characteristics and Clinical Correlates.

Authors:  María Teresa Alcántara-Garcés; Alejandra Monserrat Rodríguez-Ramírez; Ana Cristina García-Ulloa; Sergio Hernández-Jiménez
Journal:  Neuropsychiatr Dis Treat       Date:  2022-06-12       Impact factor: 2.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.